Contact us Demo our platform

Metabolon @

Microbiome Times Partnering Forum 2025 

Dates: March 18–19, 2025 
Location: Dome Event Hall, Brussels 
Visit the Official Event Website 

Join Metabolon at the Microbiome Times Partnering Forum 2025 

Metabolon is attending the Microbiome Times Partnering Forum 2025, an industry event bringing together experts in microbiome research, probiotics, and gut health innovations. This forum serves as a key meeting point for scientists, biopharma leaders, and regulatory professionals to explore the latest developments in microbiome-based therapeutics, precision nutrition, and next-generation probiotics. 

About the Microbiome Times Partnering Forum 2025 

The Microbiome Times Partnering Forum is a dedicated event focused on collaborations and business development in the microbiome space. With sessions covering scientific breakthroughs, clinical advancements, commercialization strategies, and regulatory pathways, attendees will gain valuable insights into the evolving microbiome industry. 

The forum fosters partnerships between biotechs, pharma companies, and academic researchers, providing a platform for deal-making, funding opportunities, and strategic networking. 

Scientific Themes and Program Highlights 

The Microbiome Times Partnering Forum 2025 will feature discussions on the latest advancements in microbiome science, commercialization strategies, and investment opportunities, with key themes including: 

  • Microbiome and Human Health – Understanding the impact of gut microbiota on metabolic, immune, and neurological diseases. 
  • Microbiome-Based Drug Development – Advances in live biotherapeutics, postbiotics, and microbiome-derived therapeutics. 
  • Probiotics, Prebiotics, and Synbiotics – Novel formulations and efficacy data for gut health, dermatology, and metabolic conditions. 
  • Microbiome and Metabolomics – Unlocking the functional impact of microbial communities through metabolic profiling. 
  • Regulatory & Commercialization Strategies – Addressing challenges in clinical validation, regulatory approval, and market access. 

View the Speakers & Program 

Why Metabolon is Attending the Microbiome Times Partnering Forum 2025 

Metabolon is at the forefront of microbiome research, delivering high-resolution metabolomics solutions that provide functional insights into microbial activity and host interactions. As microbiome research shifts toward high-volume data generation and integrated multiomics approaches, metabolomics has become an essential tool for biomarker discovery, microbiome-based drug development, and clinical success. 

At the Microbiome Times Partnering Forum 2025, Metabolon will be discussing: 

  • Characterizing microbiome-derived metabolites, revealing their functional roles in human health, disease, and therapeutic response. 
  • Supporting microbiome-based drug discovery, helping biopharma partners develop next-generation probiotics and live biotherapeutics. 
  • Enabling multiomics data integration through our Integrated Bioinformatics Platform, combining metabolomics, metagenomics, and proteomics for comprehensive microbiome analysis. 
  • Uncovering novel biomarkers for gut health, immune modulation, and metabolic disorders, advancing clinical microbiome research and personalized medicine. 
  • Enhancing regulatory and commercial strategies by providing validated, high-quality metabolic data for product development and clinical validation. 

With microbiome-targeted therapies gaining momentum, Metabolon provides unparalleled data quality, scalability, and actionable insights to accelerate research, development, and commercialization.  

Meet us at the Microbiome Times Partnering Forum 2025 to learn how our cutting-edge metabolomics solutions can help transform microbiome innovation. 

Schedule a Meeting

Latest Resources

Access a wealth of valuable resources to deepen your understanding about metabolomics and the scientific advancements it has empowered.

✕

References

1. Zgoda-Pols, J.R., et al., Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol, 2011. 255(1): p. 48-56.

2. Bryant, J.A., et al., The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. Nat Med, 2026. 32(1): p. 186-196

3. McGovern, B .H., et al., SER-109, an Investigational Microbiome Drugto Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis, 2021. 72(12): p. 2132-2140.

4. Feuerstadt, P., et al., SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med, 2022. 386(3): p. 220-229.

5. Hu, Z., et al., Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer. Mol Oncol, 2025. 19(6): p. 1737-1750.

6. Butler, F.M., et al., Vegetarian Dietary Patterns and Diet-Related Metabolites Are Associated With Kidney Function in the Adventist Health Study-2 Cohort. J Ren Nutr, 2025.

7. Stanford, J., et al., Metabolomic Profiling and Diet Quality Scoring in a Randomized Crossover Trial of Healthy and Typical Dietary Patterns. Mol Nutr Food Res, 2025 . 69(23): p. e70271.

8. O’Connor, L.E., et al., Metabolomic Profiling of an Ultraprocessed Dietary Pattern in a Domiciled Randomized Controlled Crossover Feeding Trial. J Nutr, 2023. 153(8): p. 2181-2192.

9. Fritsch, D.A., et al., Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Vet Res, 2022. 18(1): p. 245.

10. Leal, L.N., et al., Preweaning nutrient supply improves lactation productivity and reduces the risk of culling in Holstein cows. J Dairy Sci, 2025. 108(6): p. 5875-5888.

11. Ahsin, M., et al., Soil and pasture health underlie improved beef nutrient density determined by untargeted metabolomics in Southern US grass finished beef systems. NPJ Sci Food, 2025. 9(1): p. 151.

12. Yin, W., et al., Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res, 2012. 53(1): p. 51-65.

13. Porter, F .D., et al., Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med, 2010. 2(56): p. 56ra81.

14. Needham, B .D., et al., Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder. Biol Psychiatry, 2021. 89(5): p. 451-462

15. Li, C., et al., Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med, 2014. 211(1): p. 15-28.

16. Green, P.G., et al., Metabolic flexibility and reverse remodelling of the failing human heart. Eur Heart J, 2025. 46(25): p. 2422-2433.

17. Maekawa, H., et al., SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress. J Clin Invest, 2025. 135(19).

18. Wu, D., et al., Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition. Gut, 2026.

19. Schwerdtfeger, L.A., et al., Gut microbiota and metabolites are linked to disease progression in multiple sclerosis. Cell Rep Med, 2025. 6(4): p. 102055.

20. Wu, H., et al., Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. Nat Med, 2025. 31(7): p. 2222-2231.

21. Jacobs, J.P., et al., Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome, 2021. 9(1): p. 236.

22. Pietzner, M., et al., Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med, 2021. 27(3): p. 471-479.

23. Faquih, T.O., et al., Robust Metabolomic Age Prediction Based on a Wide Selection of Metabolites. J Gerontol A Biol Sci Med Sci, 2025. 80(3).

24. Scherer, N., et al., Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet, 2025. 57(1): p. 193-205.

25. Holmes, Z.C., et al., Untargeted metabolomic analysis of human milk from healthy mothers reveals drivers of metabolite variability. Sci Rep, 2024. 14(1): p. 20827.

26. Titz, B., et al., Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal Diseases. Transl Vis Sci Technol, 2024. 13(6): p. 17.

27. Bloom, S.M., et al., Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol, 2022. 7(3): p. 434-450.

28. Leimer, E.M., et al., Lipid profile of human synovial fluid following intra-articular ankle fracture. J Orthop Res, 2017. 35(3): p. 657-666.